Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
Michael Kaiser,Rama Abdin,Simonetta I Gaumond,Naiem T Issa,Joaquin J Jimenez
DOI: https://doi.org/10.2147/CCID.S385861
2023-05-31
Abstract:Michael Kaiser, 1 Rama Abdin, 2 Simonetta I Gaumond, 1 Naiem T Issa, 3, 4 Joaquin J Jimenez 1 1 Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; 2 Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA; 3 Forefront Dermatology, Vienna, VA, USA; 4 Issa Research and Consulting, LLC, Springfield, VA, USA Correspondence: Joaquin J Jimenez, Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA, Tel +1 305-243-6586, Email Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women. Traditionally, topical minoxidil and oral finasteride have been the standard of care yielding mixed results. New treatments such as Low-Level Laser Therapy (LLLT), microneedling, platelet-rich plasma (PRP), and others have been extensively studied in the literature, and the purpose of this review is to provide a comprehensive discussion of the latest treatment methods and their efficacy in treating AGA. Novel therapies such as oral minoxidil, topical finasteride, topical spironolactone, botulinum toxin, and stem cell therapy offer interesting alternatives to standard of care therapies for patients. In this review, we present data from recent studies on the clinical efficacy of these treatments. Furthermore, as new treatments have emerged, clinicians have tested combination therapies to assess whether there may be a synergistic relationship between multiple modalities. While there has been a great increase in the treatments available for AGA, the quality of evidence varies greatly and there is still a great need for randomized double blinded clinical trials to adequately assess the clinical efficacy of some treatments. While PRP and LLLT have demonstrated encouraging results, standardized treatment protocols are needed to adequately inform clinicians on how to use such therapies. Given the abundance of new therapeutic options, clinicians and patients must weigh the benefits and risks of each treatment option for AGA. Keywords: androgenetic alopecia, minoxidil, finasteride, platelet rich plasma, microneedling Male Pattern Hair Loss (MPHL) and Female Pattern Hair Loss (FPHL), also known as androgenetic alopecia (AGA), is the most common cause of hair loss. 1 An estimated 30% of Caucasian men will suffer from AGA by the age of 30, and approximately 80% of patients aged 70 and older are affected by AGA as prevalence increases with age. 1 Roughly 50% of females are affected by AGA. 2 The principal cause of AGA is thought to involve changes in androgen metabolism with increased age leading to progressive shortening of the anagen phase of hair growth and a decline in hair follicle size. 3 Additionally, there is an increased telogen period leading to involution of the hair follicle. 4 The increased activation of androgen receptors in AGA progressively shortens hair follicles until they can no longer penetrate through the epidermis. 5 Patients with AGA have been found to have higher levels of dihydrotestosterone (DHT), and regions of scalp affected by AGA have increased androgen receptors. 5 AGA involves the loss of terminal hairs and replacement with small vellus hairs usually in the temporal, vertex, and mid-frontal areas of the scalp. 6 The typical pattern of hair loss in AGA begins with a bitemporal recession of the hairline followed by vertex hair thinning. 7 In women, AGA typically affects the crown and bitemporal scalp areas without affecting the frontal hairline. 4 Minoxidil and finasteride remain the only medical treatments approved by the Food and Drug administration (FDA), and the Lasermax Haircomb is the only device approved by the FDA for treatment by the AGA. 8 Given the inconsistent results and dissatisfactory adverse effects associated with each, alternative treatments have been evaluated for the treatment of AGA. In this review, we will examine and present data on the clinical efficacy of the multitude of treatments available for AGA and give recommendations on quality of evidence supporting these treatment claims. The initial research and development of topical minoxidil for the treatment of AGA began in 1960. 9 Minoxidil was originally developed as an oral treatment for hypertension. 10 The main side effect was found to be hypertrichosis, which gave rise to the first topical solutions aimed at combatting hair loss. 10 Minoxidil is a prodrug that must be converted to its bioactive metabolite, minoxidil sulfate, via SULT1A sulfotransferase residing within the hair follicle. 1 -Abstract Truncated-
dermatology